GSK ranked first among global pharmaceuticals
GlaxoSmithKline (GSK) has been ranked first among global
pharmaceuticals companies assessed for their efforts to improve access
to medicine in developing countries, in the 2012 Access to Medicine
(ATM) Index released recently by the Access to Medicine Foundation.
An independent initiative, the Access to Medicine Index ranks the
world’s 20 largest companies according to their efforts to make their
products more available, affordable and accessible in developing
countries, highlighting policy and practice that either facilitate or
hinder access to medicine.
Stuart Chapman |
The Index, which is published every two years, gave GSK a score of
3.8 out of a possible maximum of five, following an in-depth evaluation
of company activities in seven areas considered to be key to enhancing
access to medicine in developing countries -- drug donation and
philanthropy, capability advancement, patents and licensing, equitable
pricing, research and development, public policy, and general access to
medicines management.
GlaxoSmithKline led the field in four out of the seven key areas and
was in the top three in others, enabling the company to retain its
position at the top of the index for the third successive time.
The Index covers 20 companies, 103 countries, and a broad range of
products such as drugs, vaccines, diagnostic tests and other
health-related technologies necessary for preventing, diagnosing and
treating disease. A total of 33 diseases are covered, and the disease
scope this year included maternal conditions and neonatal infections.
Within the seven areas on which companies are scored, the Index
analyses 101 indicators to assess the level of commitment the company
demonstrates, how transparent it is about what it is doing, what
specific activities it is engaged in and how innovative its approach is.
In its report for 2012, the Netherlands headquartered not-for-profit
Access to Medicine Foundation reported that “With visible leadership
from the top, GlaxoSmithKline continues to outperform the field, with
consistent good practice relative to peers across all areas. “It is
transparent about its activities and is the most innovative company in
terms of the way in which it manages access to medicine and approaches
research and development and building capability in developing
countries.”
Commenting on this globally significant accolade, Stuart Chapman,
Managing Director of GlaxoSmithKline Pharmaceuticals Sri Lanka said:
“Although access to medicine is a basic social right, it is estimated
that more than a billion people do not have access to the medicine they
need.
“That is why improving access to medicine has been at the core of
GSK’s overall strategy, particularly under the leadership of CEO Sir
Andrew Witty.” |